Valeria Visconte

List of Publications by Year in Descending Order

100 papers	1,608 citations	17 h-index	39 g-index
106 ext. papers	1,993 ext. citations	4.6 avg, IF	4.33 L-index

#	Paper	IF	Citations
100	Clonal dynamics of hematopoietic stem cell compartment in aplastic anemia.. *Seminars in Hematology*, **2022**, 59, 47-53	4	0
99	A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia.. *Hematological Oncology*, **2022**,	1.3	0
98	The Similarity of Class II HLA Genotypes Defines Patterns of Autoreactivity in Idiopathic Bone Marrow Failure Disorders. *Blood*, **2021**,	2.2	2
97	Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria. *Blood Cancer Journal*, **2021**, 11, 187	7	2
96	TERT Rare Variants in Myeloid Neoplasia: Lack of Clinical Impact or Role as Risk Alleles. *Blood*, **2021**, 138, 1537-1537	2.2	0
95	"We cannot paint them all with the same brush": the need for a better definition of patients with myelodysplastic syndromes for clinical trial design. *British Journal of Haematology*, **2021**, 196, 268	4.5	1
94	Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. *Blood*, **2021**, 137, 3685-3689	2.2	12
93	The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
92	Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia. *Blood Cells, Molecules, and Diseases*, **2021**, 88, 102549	2.1	0
91	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. *Blood*, **2021**, 138, 1885-1895	2.2	3
90	Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. *Blood Cells, Molecules, and Diseases* , **2021**, 87, 102528	2.1	3
89	Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. *Leukemia and Lymphoma*, **2021**, 62, 735-738	1.9	2
88	Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments. *Cancers*, **2021**, 13,	6.6	6
87	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. *Leukemia*, **2021**, 35, 3324-3328	10.7	0
86	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. *JCI Insight*, **2021**, 6,	9.9	2
85	Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?. *Blood Cells, Molecules, and Diseases*, **2021**, 91, 102595	2.1	1
84	Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. *Leukemia*, **2021**, 35, 2431-2434	10.7	3

83	From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. *Cancers*, **2020**, 12,	6.6	7
82	Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. *British Journal of Haematology*, **2020**, 189, 318-322	4.5	3
81	Co-Existence of Splicing Factor Mutations in Myeloid Malignancies. *Blood*, **2020**, 136, 33-34	2.2	
80	Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles. *Blood*, **2020**, 136, 25-25	2.2	
79	Immunogenomics of Paroxysmal Nocturnal Hemoglobinuria: A Model of Immune Escape. *Blood*, **2020**, 136, 21-22	2.2	
78	Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. *Blood*, **2020**, 136, 2-3	2.2	
77	Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms. *Blood*, **2020**, 136, 28-28	2.2	
76	Molecular and Clinical Aspects of Acute Myeloid Leukemia with Inv(3)(q21q26)/t(3;3)(q21;q26) Carrying Spliceosomal Mutations. *Blood*, **2020**, 136, 7-8	2.2	0
75	The Genomic Landscape of WilmsRTumor 1 (WT1) Mutant Acute Myeloid Leukemia. *Blood*, **2020**, 136, 28-28	2.2	
74	Molecular and Expression Characterization of Monosomy 7 and Del(7q). *Blood*, **2020**, 136, 33-33	2.2	
73	Implication of Piga Genotype on Clinical Features of PNH. *Blood*, **2020**, 136, 34-35	2.2	
72	Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia. *Blood*, **2020**, 136, 34-35	2.2	
71	Immunogenomics of Aplastic Anemia: The Role of HLA Somatic Mutations and the HLA Evolutionary Divergence. *Blood*, **2020**, 136, 20-21	2.2	
70	Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and Are Associated with Increased Circulating Burden of Microbial DNA. *Blood*, **2020**, 136, 2-3	2.2	
69	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. *Blood*, **2020**, 136, 21-21	2.2	
68	Genomic Landscape of Splicing Factor Mutant Acute Myeloid Leukemia. *Blood*, **2020**, 136, 36-36	2.2	
67	Comparative Genomic Analysis of Adolescents and Young Adults Versus Elderly with Acute Myeloid Leukemia. *Blood*, **2020**, 136, 18-18	2.2	
66	The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia. *Blood*, **2020**, 136, 8-8	2.2	1

65	The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH. *Blood*, **2020**, 136, 2-2	2.2	1
64	Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia. *Blood*, **2020**, 136, 1-1	2.2	1
63	Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. *British Journal of Haematology*, **2020**, 188, 924-929	4.5	8
62	Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
61	The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications. *Cells*, **2020**, 9,	7.9	5
60	Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. *Communications Biology*, **2020**, 3, 493	6.7	13
59	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. *Leukemia*, **2020**, 34, 957-962	10.7	16
58	Leukemia evolving from paroxysmal nocturnal hemoglobinuria. *Leukemia*, **2020**, 34, 327-330	10.7	1
57	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. *Blood*, **2019**, 134, 2696-2696	2.2	1
56	TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia. *Blood*, **2019**, 134, 880-880	2.2	2
55	T-cell large granular lymphocytic leukemia evolution post-transplant: The Cleveland Clinic experience.. *Journal of Clinical Oncology*, **2019**, 37, e19072-e19072	2.2	
54	Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?. *Blood*, **2019**, 134, 1404-1404	2.2	2
53	CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q). *Blood*, **2019**, 134, 1281-1281	2.2	
52	Predicting the Outcome in Egyptian Patients with Severe Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Matched Sibling Donors. *Blood*, **2019**, 134, 5652-5652	2.2	
51	Molecular Characterization of EP300 Mutant Myeloid Neoplasia. *Blood*, **2019**, 134, 5043-5043	2.2	
50	Coexistence of B-Cell Dyscrasia with Large Granular Lymphocytic Leukemia. *Blood*, **2019**, 134, 3750-3750	2.2	
49	Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation. *Blood*, **2019**, 134, 1226-1226	2.2	
48	Large Granular Lymphocytic Leukemia Coexists with Clonal Hematopoiesis of Indeterminate Potential. *Blood*, **2019**, 134, 3743-3743	2.2	

47	Genetics of Monosomy 7 and Del(7q) in MDS Informs Potential Therapeutic Targets. *Blood*, **2019**, 134, 1703-1703	2.2	1
46	Invariant phenotype and molecular association of biallelic mutant myeloid neoplasia. *Blood Advances*, **2019**, 3, 339-349	7.8	18
45	Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity. *Blood Advances*, **2019**, 3, 1318-1329	7.8	14
44	Distinct clinical and biological implications of in myeloid neoplasms. *Blood Advances*, **2019**, 3, 2164-2178	7.8	12
43	Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features. *Cancers*, **2019**, 11,	6.6	33
42	Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. *Leukemia*, **2018**, 32, 230-233	10.7	39
41	Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms. *Leukemia*, **2018**, 32, 550-553	10.7	9
40	Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway. *JCI Insight*, **2018**, 3,	9.9	11
39	Analysis of Even a Limited Number of Genes Indicates a Strong Inherited Component in Otherwise Typical Sporadic MDS. *Blood*, **2018**, 132, 3074-3074	2.2	
38	Rational management approach to pure red cell aplasia. *Haematologica*, **2018**, 103, 221-230	6.6	29
37	The first concurrent diagnosis of acute symptomatic Babesiosis and chronic myeloid leukemia in a healthy young adult. *Blood Research*, **2018**, 53, 163-166	1.4	
36	Consequences of mutant TET2 on clonality and subclonal hierarchy. *Leukemia*, **2018**, 32, 1751-1761	10.7	30
35	Genomic determinants of chronic myelomonocytic leukemia. *Leukemia*, **2017**, 31, 2815-2823	10.7	61
34	Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34). *International Journal of Laboratory Hematology*, **2017**, 39, 409-417	2.5	8
33	Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms. *Leukemia*, **2017**, 31, 505-510	10.7	19
32	Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine. *Leukemia*, **2016**, 30, 1190-4	10.7	16
31	Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. *Leukemia and Lymphoma*, **2016**, 57, 212-5	1.9	6
30	Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation. *Leukemia and Lymphoma*, **2016**, 57, 193-5	1.9	4

29	Acute myeloid leukemia with inv(16)(p13.1q22), abnormal eosinophils, and absence of peripheral blood and bone marrow blasts. *American Journal of Hematology*, **2016**, 91, E273-4	7.1	1
28	A Novel Oncolytic Reovirus Immune Priming Strategy Dramatically Enhances the Efficacy of Anti-PD-L1 Antibody Therapy Against Multiple Myeloma. *Blood*, **2016**, 128, 3960-3960	2.2	2
27	Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes. *Blood*, **2016**, 128, 4301-4301	2.2	2
26	Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations. *American Journal of Hematology*, **2016**, 91, 406-9	7.1	11
25	Cyclosporine dependent pure red cell aplasia: a case presentation. *Blood Cells, Molecules, and Diseases*, **2015**, 54, 281-3	2.1	
24	Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron. *Leukemia*, **2015**, 29, 188-95	10.7	37
23	Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 489-95	2	4
22	Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2014. *Leukemia Research*, **2015**, 39, 110-3	2.7	3
21	Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia. *Leukemia and Lymphoma*, **2015**, 56, 1888-90	1.9	1
20	Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML. *Blood*, **2015**, 126, 1350-1350	2.2	0
19	Small Molecule Inhibition of SIRT Activity: A Novel Therapeutic Approach for Refractory Multiple Myeloma. *Blood*, **2015**, 126, 1807-1807	2.2	
18	Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. *Leukemia*, **2014**, 28, 1486-93	10.7	37
17	Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10). *American Journal of Hematology*, **2014**, 89, 862	7.1	9
16	Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. *Leukemia Research*, **2014**, 38, 1245-51	2.7	38
15	Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. *Blood Research*, **2014**, 49, 216-27	1.4	38
14	Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts. *Journal of Hematology and Oncology*, **2014**, 7, 89	22.4	16
13	Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. *Cell Reports*, **2014**, 9, 1333-48	10.6	41
12	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. *Leukemia*, **2014**, 28, 78-87	10.7	226

11	Molecular pathogenesis of myelodysplastic syndromes. *Translational Medicine @ UniSa*, **2014**, 8, 19-30	0.5	10
10	A case of mistaken identity: When lupus masquerades as primary myelofibrosis. *SAGE Open Medical Case Reports*, **2013**, 1, 2050313X13498709	0.7	2
9	SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype. *Haematologica*, **2013**, 98, e105-7	6.6	11
8	Splicing Factor 3b Subunit 1 (SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 (SLC25A37). *Blood*, **2013**, 122, 1555-1555	2.2	1
7	Spliceosome Gene Mutations Are Frequently Found In JAK2 Negative Myelofibrosis and Associated With Worse Clinical Outcomes. *Blood*, **2013**, 122, 4063-4063	2.2	
6	SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. *Leukemia*, **2012**, 26, 542-5	10.7	178
5	SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. *Blood*, **2012**, 120, 3173-86	2.2	152
4	Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. *Leukemia*, **2012**, 26, 2447-54	10.7	82
3	Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. *Blood*, **2012**, 119, 3203-10	2.2	293
2	Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in Patients with Myeloid Malignancies Who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2012**, 120, 1973-1973	2.2	1
1	Acquired Molecular Defects in Spliceosome Machinery: Novel Pathogenetic Pathways in Myeloid Leukemogenesis. *Blood*, **2011**, 118, 271-271	2.2	